Biomedical Engineering Reference
In-Depth Information
66. Montagut, C,
. (2008). Elevated CRAF as a potential mechanism of
acquired resistance to BRAF inhibition in melanoma,
et al
Cancer Res
.,
68
,
pp. 4853-4861.
67. Emery, CM,
. (2009). MEK1 mutations confer resistance to MEK
and B-RAF inhibition,
et al
Proc Natl Acad Sci USA
,
106
, pp. 20411-20416.
68. Johannessen, C,
. (2010). COT drives resistance to RAF inhibition
through MAP kinase pathway reactivation,
et al
Nature
,
468
, pp. 968-972.
69. Casa, AJ,
. (2008). The type I insulin-like growth factor receptor
pathway: a key player in cancer therapeutic resistance,
et al
Front Biosci.,
, pp. 3273-87.
70. Smalley, KS,
13
. (2008). Increased cyclin D1 expression can mediate
BRAF inhibitor resistance in BRAF V600E-mutated melanomas,
et al
Mol
Cancer Ther
.,
7
, pp. 2876-2883.
71. Nazarian,
R,
et
al
.
(2010).
Melanomas
acquire
resistance
to
B-RAF(V600E) inhibition by RTK or N-RAS up regulation,
Nature
,
468
,
pp. 973-977.
72. Gray-Schopfer, VC,
. (2007). Tumor necrosis factor-(alpha) blocks
apoptosis in melanoma cells when BRAF signaling is inhibited,
et al
Cancer
Res
.,
67
, pp. 122-129.
